Celldex, Pfizer deal

Celldex said Pfizer's Pfizer Vaccines LLC division will terminate a 2008 deal and return all rights to develop and commercialize rindopepimut ( CDX-110), effective Nov. 1. According to Celldex, Pfizer said the glioblastoma multiforme (GBM) candidate was no longer a strategic priority. Celldex said it plans to continue development of the vaccine targeting EGFR variant III ( EGFRvIII), which is in Phase IIb testing. The product has Fast Track and Orphan Drug designations in the U.S. for the indication (see BioCentury April 21, 2008). ...